BTIG Downgrades Aclaris Therapeutics to Neutral
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Julian Harrison has downgraded Aclaris Therapeutics (NASDAQ: ACRS) from Buy to Neutral. The downgrade could influence the stock's performance in the short term as investors adjust to the new rating.
January 11, 2024 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Aclaris Therapeutics was downgraded by BTIG analyst Julian Harrison from Buy to Neutral, which may lead to a negative short term impact on the stock as market sentiment adjusts.
Analyst ratings often influence investor sentiment and can lead to stock price movements. A downgrade from Buy to Neutral suggests a less optimistic outlook on the stock, which could result in a decrease in investor interest and a potential drop in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100